Abstract
<p>Comparison between the <i>in vitro</i> antiproliferative activities of BI-847325 and the MEK inhibitor GDC-0623. <b>A,</b> Contingency table with counts of CLs per class of sensitivity to BI-847325 and GDC-0623 (cutoff for Abs IC<sub>70</sub> values for both compounds: ≤ 1 µmol/L; statistics: Fisher exact test, significance: <i>P</i> < 0.05). <b>B,</b> Correlation plot of BI-847325 and GDC-0623 Abs IC<sub>70</sub> values for 276 CLs. Dark blue circles: CLs derived from solid tumors, Dark red circles: CLs derived from hematologic cancers. <b>C,</b> Counts of CLs per tumor type being sensitive to GDC-0623 and/or BI-847325 (Abs IC<sub>70</sub> ≤ 1µmol/L). Dark blue bars: CLs sensitive to both GDC-0623 and BI-847325, Green bars: CLs sensitive to BI-847325 only. The total number of CLs per tumor type is indicated in black on the right of each bar.</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
